Riferimento farmaci
Lazertinib
Lazertinib is a medicine in the class oncology. It is used for non-small cell lung cancer.
- Classe del farmaco: Oncology
- Indicato per: non-small cell lung cancer
Ultimo aggiornamento Fonti: US FDA label
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
In breve
- Classe del farmaco
- Oncology
- Codice ATC
- L01EB09
- Forme farmaceutiche comuni
- compressa
- Interazioni note
- 1 (Moderata: 1)
- Nomi commerciali
- 2
- Paesi e mercati
- 2
Per cosa si usa
Come agisce
Kinase inhibitor of EGFR that inhibits EGFR exon 19 deletions and exon 21 L858R substitution mutations at lower concentrations than wild-type EGFR.
Dose abituale nell'adulto (sintesi del foglio illustrativo)
First-line EGFR-mutated NSCLC (exon 19 deletion or exon 21 L858R), with amivantamab: 240 mg orally once daily with or without food; continue until disease progression or unacceptable toxicity; give any time prior to amivantamab on the same day.
Gravidanza e allattamento
- Gravidanza
- Unsafe Can cause fetal harm: no human data; in animals it reduced embryo-fetal survival and fetal weight (rats) and caused malformations (rabbits) at about 4 and 0.5 times human exposure. Verify pregnancy status and use effective contraception during and for 3 weeks after treatment.
- Allattamento
- Unsafe No data on milk levels or infant effects. Because of possible serious adverse reactions in the infant, do not breastfeed during treatment and for 3 weeks after the last dose; follow the amivantamab label for the combination.
Effetti indesiderati segnalati
- Rash
- Nail toxicity
- Musculoskeletal pain
- Edema
- Stomatitis
- Venous thromboembolism
Controindicazioni
- None.
Chi deve prestare attenzione
- Serious and fatal VTE (36% in MARIPOSA); give prophylactic anticoagulation for the first four months; vitamin K antagonists are not recommended.
- ILD/pneumonitis can occur; monitor for symptoms, withhold if suspected, discontinue if confirmed.
- Severe dermatologic reactions including rash; prophylactic measures recommended; limit sun exposure.
Informare il farmacista o il medico di gravidanza o allattamento, malattie renali o epatiche, allergie e di ogni altro farmaco o integratore assunto.
Interazioni principali (1)
- Amivantamab + Lazertinib Moderate
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per aprire la monografia completa di Lazertinib: dosi, gravidanza e allattamento, effetti indesiderati, avvertenze e tutte le interazioni.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Provi Pro+ gratis per 14 giorni sul web. Nessuna carta.
Altri farmaci della stessa classe
Domande frequenti
What is Lazertinib used for?
Lazertinib is a medicine in the class oncology. It is used for Non-small cell lung cancer.
What side effects have been reported with Lazertinib?
Rash, Nail toxicity, Musculoskeletal pain, Edema, Stomatitis, Venous thromboembolism.
Can Lazertinib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: no human data; in animals it reduced embryo-fetal survival and fetal weight (rats) and caused malformations (rabbits) at about 4 and 0.5 times human exposure. Verify pregnancy status and use effective contraception during and for 3 weeks after treatment. Breastfeeding: Unsafe. No data on milk levels or infant effects. Because of possible serious adverse reactions in the infant, do not breastfeed during treatment and for 3 weeks after the last dose; follow the amivantamab label for the combination.
What does Lazertinib interact with?
MediHelp lists 1 known interactions for Lazertinib. Moderate: 1. The most serious include Amivantamab.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
